LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

LLY

1,107.1

+0.49%↑

JNJ

240.14

+2.2%↑

ABBV

234.01

-0.14%↓

UNH

402.54

-0.87%↓

MRK

119.77

+1.35%↑

Search

Day One Biopharmaceuticals Inc

Deschisă

SectorSănătate

21.45

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

Indicatori cheie

By Trading Economics

Venit

-1.6M

-21M

Vânzări

14M

54M

Marjă de profit

-39.611

Angajați

178

EBITDA

-7.7M

-26M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-3.62% downside

Statistici piață

By TradingEconomics

Capitalizare de piață

1B

2.2B

Deschiderea anterioară

21.45

Închiderea anterioară

21.45

Sentimentul știrilor

By Acuity

50%

50%

143 / 342 Clasament în Healthcare

Day One Biopharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Despre Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
help-icon Live chat